Taken together, these observations suggest that, independent of amyloid pathology, pathologic tau induces a two‐phase neuroimmune response: the first phase is characterized by cytoskeletal disruption concomitant with high microglial activity, and the second phase is marked by frank neuronal loss coupled with high levels of astrogliosis. This evidence concerns the gene MAPT and amyloidosis.